MA42614A - Dérivés d'acide 5-(n-benzyl tétrahydroisoquinolin-6-yl) pyridin-3-yl-acétique utilisés comme inhibiteurs de la réplication du virus de l'immunodéficience humaine - Google Patents

Dérivés d'acide 5-(n-benzyl tétrahydroisoquinolin-6-yl) pyridin-3-yl-acétique utilisés comme inhibiteurs de la réplication du virus de l'immunodéficience humaine

Info

Publication number
MA42614A
MA42614A MA042614A MA42614A MA42614A MA 42614 A MA42614 A MA 42614A MA 042614 A MA042614 A MA 042614A MA 42614 A MA42614 A MA 42614A MA 42614 A MA42614 A MA 42614A
Authority
MA
Morocco
Prior art keywords
tetrahydroisoquinolin
pyridin
benzyl
acetic acid
acid derivatives
Prior art date
Application number
MA042614A
Other languages
English (en)
Inventor
Kyle J Eastman
John F Kadow
B Narasimhulu Naidu
Kyle E Parcella
Tao Wang
Zhiwei Yin
Zhongxing Zhang
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56851651&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA42614(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of MA42614A publication Critical patent/MA42614A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA042614A 2015-08-11 2016-08-10 Dérivés d'acide 5-(n-benzyl tétrahydroisoquinolin-6-yl) pyridin-3-yl-acétique utilisés comme inhibiteurs de la réplication du virus de l'immunodéficience humaine MA42614A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562203791P 2015-08-11 2015-08-11

Publications (1)

Publication Number Publication Date
MA42614A true MA42614A (fr) 2021-05-26

Family

ID=56851651

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042614A MA42614A (fr) 2015-08-11 2016-08-10 Dérivés d'acide 5-(n-benzyl tétrahydroisoquinolin-6-yl) pyridin-3-yl-acétique utilisés comme inhibiteurs de la réplication du virus de l'immunodéficience humaine

Country Status (23)

Country Link
US (2) US10189816B2 (fr)
EP (1) EP3334716A1 (fr)
JP (1) JP6782766B2 (fr)
KR (1) KR20180032649A (fr)
CN (1) CN108137534A (fr)
AR (1) AR105653A1 (fr)
AU (1) AU2016306089B2 (fr)
CA (1) CA2994791A1 (fr)
CL (1) CL2018000363A1 (fr)
CO (1) CO2018001359A2 (fr)
CR (1) CR20180091A (fr)
DO (1) DOP2018000035A (fr)
EA (1) EA033057B1 (fr)
HK (1) HK1249503A1 (fr)
IL (1) IL257240B (fr)
MA (1) MA42614A (fr)
MX (1) MX2018001722A (fr)
PE (1) PE20181002A1 (fr)
PH (1) PH12018500294A1 (fr)
TW (1) TWI657086B (fr)
UA (1) UA120464C2 (fr)
WO (1) WO2017025917A1 (fr)
ZA (1) ZA201800689B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201718537A (zh) * 2015-08-12 2017-06-01 Viiv醫療保健英國(No.5)有限公司 做為人類免疫缺陷病毒複製抑制劑之吡啶-3-基乙酸衍生物
KR20180032650A (ko) * 2015-08-12 2018-03-30 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제로서 5-(n-[6,5]-융합된 바이사이클릭 아릴 테트라하이드로이소퀴놀린-6-일) 피리딘-3-일 아세트산 유도체
EP3455217A1 (fr) * 2016-05-11 2019-03-20 ViiV Healthcare UK (No.5) Limited Dérivés d'acide pyridin-3-yle acétique utilisés comme inhibiteurs de la réplication du virus de l'immunodéficience humaine
US20190152957A1 (en) * 2016-05-11 2019-05-23 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP3455215A1 (fr) * 2016-05-11 2019-03-20 ViiV Healthcare UK (No.5) Limited Dérivés d'acide pyridin-3-yle acétique utilisés comme inhibiteurs de la réplication du virus de l'immunodéficience humaine
WO2018127801A1 (fr) * 2017-01-03 2018-07-12 VIIV Healthcare UK (No.5) Limited Dérivés d'acide pyridin-3-yle acétique utilisés en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
TW201835068A (zh) * 2017-01-03 2018-10-01 英商Viiv醫療保健英國(No.5)有限公司 作為人類免疫缺乏病毒複製之抑制劑之吡啶-3-基乙酸衍生物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939545B2 (en) 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
HRP20120328T2 (hr) 2007-11-15 2012-09-30 Gilead Sciences Inhibitori replikacije virusa humane imunodeficijencije
EP2574610A1 (fr) 2007-11-15 2013-04-03 Gilead Sciences, Inc. Inhibiteurs de la réplication du virus de l'immunodéficience humaine
CA2705338A1 (fr) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibiteurs de la replication du virus de l'immunodeficience humaine
WO2009062285A1 (fr) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibiteurs de la réplication du virus de l'immunodéficience humaine
US8338441B2 (en) * 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
KR101483834B1 (ko) 2009-12-23 2015-01-16 카트호리이케 유니버시타이트 로이펜 항바이러스 화합물
US8633200B2 (en) 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US8629276B2 (en) 2012-02-15 2014-01-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9580431B2 (en) 2013-03-13 2017-02-28 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP2970274B1 (fr) 2013-03-14 2017-03-01 VIIV Healthcare UK (No.5) Limited Inhibiteurs de la réplication du virus de l'immunodéficience humaine
PT3116880T (pt) * 2014-02-20 2018-05-10 Viiv Healthcare Uk No 5 Ltd Macrociclos de ácido piridin-3-il acético como inibidores da replicação do vírus da imunodeficiência humana
US9193720B2 (en) 2014-02-20 2015-11-24 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
TW201718537A (zh) * 2015-08-12 2017-06-01 Viiv醫療保健英國(No.5)有限公司 做為人類免疫缺陷病毒複製抑制劑之吡啶-3-基乙酸衍生物
KR20180032650A (ko) * 2015-08-12 2018-03-30 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제로서 5-(n-[6,5]-융합된 바이사이클릭 아릴 테트라하이드로이소퀴놀린-6-일) 피리딘-3-일 아세트산 유도체
CA2995087A1 (fr) * 2015-08-12 2017-02-16 John F. Kadow Derives tricycliques condenses d'acide 5-(n-aryle tetrahydroisoquinoline-6-yl) pyridin-3-yl acetique comme inhibiteurs de la replication du virus d'immunodeficience humaine

Also Published As

Publication number Publication date
PE20181002A1 (es) 2018-06-26
HK1249503A1 (zh) 2018-11-02
UA120464C2 (uk) 2019-12-10
CA2994791A1 (fr) 2017-02-16
CO2018001359A2 (es) 2018-05-10
ZA201800689B (en) 2021-08-25
WO2017025917A1 (fr) 2017-02-16
IL257240A (en) 2018-03-29
IL257240B (en) 2020-02-27
MX2018001722A (es) 2018-05-16
TW201718549A (zh) 2017-06-01
US20190092754A1 (en) 2019-03-28
AR105653A1 (es) 2017-10-25
JP2018522927A (ja) 2018-08-16
EA033057B1 (ru) 2019-08-30
US20180230129A1 (en) 2018-08-16
JP6782766B2 (ja) 2020-11-11
EA201890361A1 (ru) 2018-11-30
CL2018000363A1 (es) 2018-07-06
KR20180032649A (ko) 2018-03-30
US10189816B2 (en) 2019-01-29
EP3334716A1 (fr) 2018-06-20
AU2016306089A1 (en) 2018-03-01
TWI657086B (zh) 2019-04-21
CN108137534A (zh) 2018-06-08
CR20180091A (es) 2018-06-13
AU2016306089B2 (en) 2018-08-09
DOP2018000035A (es) 2018-03-30
PH12018500294A1 (en) 2018-08-13

Similar Documents

Publication Publication Date Title
EA201792354A1 (ru) Композиции обетихолевой кислоты и способы применения
MA44077A (fr) Anticorps neutralisants le virus de l'immunodéficience humaine
CY1123417T1 (el) Παραγωγα τετρα�δροϊσοκινολινης
MA53973A (fr) Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP3402787A4 (fr) Procédés de préparation d'acide 2,5-furandicarboxylique et des intermédiaires et dérivés correspondants
EP3517528A4 (fr) Sel d'addition d'acide de dérivé de benzimidazole
EP3353189A4 (fr) Procédés et intermédiaires pour la préparation de dérivés de l'acide biliaire
EA201790024A1 (ru) Модуляторы toll-подобных рецепторов для лечения вич
EP3491149A4 (fr) Traitement d'acide nucléique indépendant
EA201790630A1 (ru) Способы получения рибозидов
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
EP3529232A4 (fr) Dérivés d'acide sulfamique et procédés pour leur préparation
EP3377066A4 (fr) Dérivés de pyridotriazine amido-substitués utiles en tant qu'inhibiteurs de l'intégrase du vih
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
MX382122B (es) Oxiesteroles y metodos de uso de los mismos.
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
PL3346995T3 (pl) Kompozycje terapeutyczne do leczenia ludzkiego wirusa niedoboru odporności
EP3887402A4 (fr) Plaquettes utilisées comme agents d'administration
MA41341A (fr) Dérivés indole utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
EA201791896A1 (ru) Дезацетокситубулизин н и его аналоги
EA201692034A1 (ru) Новые макроциклические соединения